Global OTC Drug

OTC Drug Comprehensive Study by Type (Class A, Class B), Application (Allergy Prevention & Treatment, Antacids and Acid Reducers, Anticandial, Antihistamines, Antidiarrheal and Laxatives, Anti-fungal, Asthma, Others), (), Form (Liquid, Powder, Tablets), End User (Hospital, Clinic, Household) Players and Region - Global Market Outlook to 2032

OTC Drug Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About OTC Drug
Every year the trend of OTC drug use has increased steadily in the last few years. Several reasons such as easy availability, affordability, and increased awareness among patients are responsible for this trend. Over-the-Counter Drugs Used Primarily for Medical Care and reimbursable with just an outsider receipt. No recommendation from a healthcare provider is required, easily accessible and are used for the treatment of minor illness. These drugs are similar in nature to regular consumables, such as food and cosmetics products. According to the research in the United States more than 80 class of over the counter medication amounting up to 1,00,000 products, additionally, the estimation also shows that each year, OTC drugs save USD 102billions in the United States and 25 Billion saved due to its use and USD 77 billion is saved as the hospital visits are avoided.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global OTC Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Eli Lily (United States), Pfizer (United States), Sanofi (France), Abbott Laboratories (United States), Amgen(United States), AstraZeneca (United Kingdom), Merck & Co. (United States), Novartis (Switzerland), Roche Holdings (Switzerland) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Lifecare Innovations (India) and GlaxoSmithKline (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global OTC Drug market by Type (Class A and Class B), Application (Allergy Prevention & Treatment, Antacids and Acid Reducers, Anticandial, Antihistamines, Antidiarrheal and Laxatives, Anti-fungal, Asthma and Others) and Region.



On the basis of geography, the market of OTC Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the OTC Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form, the sub-segment i.e. Liquid will boost the OTC Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the OTC Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The ongoing industry reorganization involving acquisitions in recent years has led to a tendency among pharmaceutical companies. and The growing trend of self-medication in developing economies

Market Growth Drivers:
Increased percentage of middle schools adopting an OTC Medicine Safety module as part of the health program

Challenges:
Preference for prescription based medicine

Restraints:
Incorrect dosage can be led to dangerous

Opportunities:
The growing demand of the developing countries market

Most recently in January 2019, clinical protection giant Anthem dispatched an association program with Walmart for policyholders of Medicare Advantage Plans, protection for old individuals, to give them better admittance to OTC medications. The arrangement gives protection inclusion to OTC medications bought at Walmart by those senior shoppers


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, OTC Drug Manufacturers, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Class A
  • Class B
By Application
  • Allergy Prevention & Treatment
  • Antacids and Acid Reducers
  • Anticandial
  • Antihistamines
  • Antidiarrheal and Laxatives
  • Anti-fungal
  • Asthma
  • Others
By Form
  • Liquid
  • Powder
  • Tablets

By End User
  • Hospital
  • Clinic
  • Household

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased percentage of middle schools adopting an OTC Medicine Safety module as part of the health program
    • 3.3. Market Challenges
      • 3.3.1. Preference for prescription based medicine
    • 3.4. Market Trends
      • 3.4.1. The ongoing industry reorganization involving acquisitions in recent years has led to a tendency among pharmaceutical companies.
      • 3.4.2. The growing trend of self-medication in developing economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global OTC Drug, by Type, Application, , Form, End User and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global OTC Drug (Value)
      • 5.2.1. Global OTC Drug by: Type (Value)
        • 5.2.1.1. Class A
        • 5.2.1.2. Class B
      • 5.2.2. Global OTC Drug by: Application (Value)
        • 5.2.2.1. Allergy Prevention & Treatment
        • 5.2.2.2. Antacids and Acid Reducers
        • 5.2.2.3. Anticandial
        • 5.2.2.4. Antihistamines
        • 5.2.2.5. Antidiarrheal and Laxatives
        • 5.2.2.6. Anti-fungal
        • 5.2.2.7. Asthma
        • 5.2.2.8. Others
      • 5.2.3. Global OTC Drug by: Form (Value)
        • 5.2.3.1. Liquid
        • 5.2.3.2. Powder
        • 5.2.3.3. Tablets
      • 5.2.4. Global OTC Drug by: End User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinic
        • 5.2.4.3. Household
      • 5.2.5. Global OTC Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. OTC Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lily (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche Holdings (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global OTC Drug Sale, by Type, Application, , Form, End User and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global OTC Drug (Value)
      • 7.2.1. Global OTC Drug by: Type (Value)
        • 7.2.1.1. Class A
        • 7.2.1.2. Class B
      • 7.2.2. Global OTC Drug by: Application (Value)
        • 7.2.2.1. Allergy Prevention & Treatment
        • 7.2.2.2. Antacids and Acid Reducers
        • 7.2.2.3. Anticandial
        • 7.2.2.4. Antihistamines
        • 7.2.2.5. Antidiarrheal and Laxatives
        • 7.2.2.6. Anti-fungal
        • 7.2.2.7. Asthma
        • 7.2.2.8. Others
      • 7.2.3. Global OTC Drug by: Form (Value)
        • 7.2.3.1. Liquid
        • 7.2.3.2. Powder
        • 7.2.3.3. Tablets
      • 7.2.4. Global OTC Drug by: End User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinic
        • 7.2.4.3. Household
      • 7.2.5. Global OTC Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. OTC Drug: by Type(USD Million)
  • Table 2. OTC Drug Class A , by Region USD Million (2019-2024)
  • Table 3. OTC Drug Class B , by Region USD Million (2019-2024)
  • Table 4. OTC Drug: by Application(USD Million)
  • Table 5. OTC Drug Allergy Prevention & Treatment , by Region USD Million (2019-2024)
  • Table 6. OTC Drug Antacids and Acid Reducers , by Region USD Million (2019-2024)
  • Table 7. OTC Drug Anticandial , by Region USD Million (2019-2024)
  • Table 8. OTC Drug Antihistamines , by Region USD Million (2019-2024)
  • Table 9. OTC Drug Antidiarrheal and Laxatives , by Region USD Million (2019-2024)
  • Table 10. OTC Drug Anti-fungal , by Region USD Million (2019-2024)
  • Table 11. OTC Drug Asthma , by Region USD Million (2019-2024)
  • Table 12. OTC Drug Others , by Region USD Million (2019-2024)
  • Table 13. OTC Drug: by Form(USD Million)
  • Table 14. OTC Drug Liquid , by Region USD Million (2019-2024)
  • Table 15. OTC Drug Powder , by Region USD Million (2019-2024)
  • Table 16. OTC Drug Tablets , by Region USD Million (2019-2024)
  • Table 17. OTC Drug: by End User(USD Million)
  • Table 18. OTC Drug Hospital , by Region USD Million (2019-2024)
  • Table 19. OTC Drug Clinic , by Region USD Million (2019-2024)
  • Table 20. OTC Drug Household , by Region USD Million (2019-2024)
  • Table 21. South America OTC Drug, by Country USD Million (2019-2024)
  • Table 22. South America OTC Drug, by Type USD Million (2019-2024)
  • Table 23. South America OTC Drug, by Application USD Million (2019-2024)
  • Table 24. South America OTC Drug, by Form USD Million (2019-2024)
  • Table 25. South America OTC Drug, by End User USD Million (2019-2024)
  • Table 26. Brazil OTC Drug, by Type USD Million (2019-2024)
  • Table 27. Brazil OTC Drug, by Application USD Million (2019-2024)
  • Table 28. Brazil OTC Drug, by Form USD Million (2019-2024)
  • Table 29. Brazil OTC Drug, by End User USD Million (2019-2024)
  • Table 30. Argentina OTC Drug, by Type USD Million (2019-2024)
  • Table 31. Argentina OTC Drug, by Application USD Million (2019-2024)
  • Table 32. Argentina OTC Drug, by Form USD Million (2019-2024)
  • Table 33. Argentina OTC Drug, by End User USD Million (2019-2024)
  • Table 34. Rest of South America OTC Drug, by Type USD Million (2019-2024)
  • Table 35. Rest of South America OTC Drug, by Application USD Million (2019-2024)
  • Table 36. Rest of South America OTC Drug, by Form USD Million (2019-2024)
  • Table 37. Rest of South America OTC Drug, by End User USD Million (2019-2024)
  • Table 38. Asia Pacific OTC Drug, by Country USD Million (2019-2024)
  • Table 39. Asia Pacific OTC Drug, by Type USD Million (2019-2024)
  • Table 40. Asia Pacific OTC Drug, by Application USD Million (2019-2024)
  • Table 41. Asia Pacific OTC Drug, by Form USD Million (2019-2024)
  • Table 42. Asia Pacific OTC Drug, by End User USD Million (2019-2024)
  • Table 43. China OTC Drug, by Type USD Million (2019-2024)
  • Table 44. China OTC Drug, by Application USD Million (2019-2024)
  • Table 45. China OTC Drug, by Form USD Million (2019-2024)
  • Table 46. China OTC Drug, by End User USD Million (2019-2024)
  • Table 47. Japan OTC Drug, by Type USD Million (2019-2024)
  • Table 48. Japan OTC Drug, by Application USD Million (2019-2024)
  • Table 49. Japan OTC Drug, by Form USD Million (2019-2024)
  • Table 50. Japan OTC Drug, by End User USD Million (2019-2024)
  • Table 51. India OTC Drug, by Type USD Million (2019-2024)
  • Table 52. India OTC Drug, by Application USD Million (2019-2024)
  • Table 53. India OTC Drug, by Form USD Million (2019-2024)
  • Table 54. India OTC Drug, by End User USD Million (2019-2024)
  • Table 55. South Korea OTC Drug, by Type USD Million (2019-2024)
  • Table 56. South Korea OTC Drug, by Application USD Million (2019-2024)
  • Table 57. South Korea OTC Drug, by Form USD Million (2019-2024)
  • Table 58. South Korea OTC Drug, by End User USD Million (2019-2024)
  • Table 59. Taiwan OTC Drug, by Type USD Million (2019-2024)
  • Table 60. Taiwan OTC Drug, by Application USD Million (2019-2024)
  • Table 61. Taiwan OTC Drug, by Form USD Million (2019-2024)
  • Table 62. Taiwan OTC Drug, by End User USD Million (2019-2024)
  • Table 63. Australia OTC Drug, by Type USD Million (2019-2024)
  • Table 64. Australia OTC Drug, by Application USD Million (2019-2024)
  • Table 65. Australia OTC Drug, by Form USD Million (2019-2024)
  • Table 66. Australia OTC Drug, by End User USD Million (2019-2024)
  • Table 67. Rest of Asia-Pacific OTC Drug, by Type USD Million (2019-2024)
  • Table 68. Rest of Asia-Pacific OTC Drug, by Application USD Million (2019-2024)
  • Table 69. Rest of Asia-Pacific OTC Drug, by Form USD Million (2019-2024)
  • Table 70. Rest of Asia-Pacific OTC Drug, by End User USD Million (2019-2024)
  • Table 71. Europe OTC Drug, by Country USD Million (2019-2024)
  • Table 72. Europe OTC Drug, by Type USD Million (2019-2024)
  • Table 73. Europe OTC Drug, by Application USD Million (2019-2024)
  • Table 74. Europe OTC Drug, by Form USD Million (2019-2024)
  • Table 75. Europe OTC Drug, by End User USD Million (2019-2024)
  • Table 76. Germany OTC Drug, by Type USD Million (2019-2024)
  • Table 77. Germany OTC Drug, by Application USD Million (2019-2024)
  • Table 78. Germany OTC Drug, by Form USD Million (2019-2024)
  • Table 79. Germany OTC Drug, by End User USD Million (2019-2024)
  • Table 80. France OTC Drug, by Type USD Million (2019-2024)
  • Table 81. France OTC Drug, by Application USD Million (2019-2024)
  • Table 82. France OTC Drug, by Form USD Million (2019-2024)
  • Table 83. France OTC Drug, by End User USD Million (2019-2024)
  • Table 84. Italy OTC Drug, by Type USD Million (2019-2024)
  • Table 85. Italy OTC Drug, by Application USD Million (2019-2024)
  • Table 86. Italy OTC Drug, by Form USD Million (2019-2024)
  • Table 87. Italy OTC Drug, by End User USD Million (2019-2024)
  • Table 88. United Kingdom OTC Drug, by Type USD Million (2019-2024)
  • Table 89. United Kingdom OTC Drug, by Application USD Million (2019-2024)
  • Table 90. United Kingdom OTC Drug, by Form USD Million (2019-2024)
  • Table 91. United Kingdom OTC Drug, by End User USD Million (2019-2024)
  • Table 92. Netherlands OTC Drug, by Type USD Million (2019-2024)
  • Table 93. Netherlands OTC Drug, by Application USD Million (2019-2024)
  • Table 94. Netherlands OTC Drug, by Form USD Million (2019-2024)
  • Table 95. Netherlands OTC Drug, by End User USD Million (2019-2024)
  • Table 96. Rest of Europe OTC Drug, by Type USD Million (2019-2024)
  • Table 97. Rest of Europe OTC Drug, by Application USD Million (2019-2024)
  • Table 98. Rest of Europe OTC Drug, by Form USD Million (2019-2024)
  • Table 99. Rest of Europe OTC Drug, by End User USD Million (2019-2024)
  • Table 100. MEA OTC Drug, by Country USD Million (2019-2024)
  • Table 101. MEA OTC Drug, by Type USD Million (2019-2024)
  • Table 102. MEA OTC Drug, by Application USD Million (2019-2024)
  • Table 103. MEA OTC Drug, by Form USD Million (2019-2024)
  • Table 104. MEA OTC Drug, by End User USD Million (2019-2024)
  • Table 105. Middle East OTC Drug, by Type USD Million (2019-2024)
  • Table 106. Middle East OTC Drug, by Application USD Million (2019-2024)
  • Table 107. Middle East OTC Drug, by Form USD Million (2019-2024)
  • Table 108. Middle East OTC Drug, by End User USD Million (2019-2024)
  • Table 109. Africa OTC Drug, by Type USD Million (2019-2024)
  • Table 110. Africa OTC Drug, by Application USD Million (2019-2024)
  • Table 111. Africa OTC Drug, by Form USD Million (2019-2024)
  • Table 112. Africa OTC Drug, by End User USD Million (2019-2024)
  • Table 113. North America OTC Drug, by Country USD Million (2019-2024)
  • Table 114. North America OTC Drug, by Type USD Million (2019-2024)
  • Table 115. North America OTC Drug, by Application USD Million (2019-2024)
  • Table 116. North America OTC Drug, by Form USD Million (2019-2024)
  • Table 117. North America OTC Drug, by End User USD Million (2019-2024)
  • Table 118. United States OTC Drug, by Type USD Million (2019-2024)
  • Table 119. United States OTC Drug, by Application USD Million (2019-2024)
  • Table 120. United States OTC Drug, by Form USD Million (2019-2024)
  • Table 121. United States OTC Drug, by End User USD Million (2019-2024)
  • Table 122. Canada OTC Drug, by Type USD Million (2019-2024)
  • Table 123. Canada OTC Drug, by Application USD Million (2019-2024)
  • Table 124. Canada OTC Drug, by Form USD Million (2019-2024)
  • Table 125. Canada OTC Drug, by End User USD Million (2019-2024)
  • Table 126. Mexico OTC Drug, by Type USD Million (2019-2024)
  • Table 127. Mexico OTC Drug, by Application USD Million (2019-2024)
  • Table 128. Mexico OTC Drug, by Form USD Million (2019-2024)
  • Table 129. Mexico OTC Drug, by End User USD Million (2019-2024)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. OTC Drug: by Type(USD Million)
  • Table 141. OTC Drug Class A , by Region USD Million (2027-2032)
  • Table 142. OTC Drug Class B , by Region USD Million (2027-2032)
  • Table 143. OTC Drug: by Application(USD Million)
  • Table 144. OTC Drug Allergy Prevention & Treatment , by Region USD Million (2027-2032)
  • Table 145. OTC Drug Antacids and Acid Reducers , by Region USD Million (2027-2032)
  • Table 146. OTC Drug Anticandial , by Region USD Million (2027-2032)
  • Table 147. OTC Drug Antihistamines , by Region USD Million (2027-2032)
  • Table 148. OTC Drug Antidiarrheal and Laxatives , by Region USD Million (2027-2032)
  • Table 149. OTC Drug Anti-fungal , by Region USD Million (2027-2032)
  • Table 150. OTC Drug Asthma , by Region USD Million (2027-2032)
  • Table 151. OTC Drug Others , by Region USD Million (2027-2032)
  • Table 152. OTC Drug: by Form(USD Million)
  • Table 153. OTC Drug Liquid , by Region USD Million (2027-2032)
  • Table 154. OTC Drug Powder , by Region USD Million (2027-2032)
  • Table 155. OTC Drug Tablets , by Region USD Million (2027-2032)
  • Table 156. OTC Drug: by End User(USD Million)
  • Table 157. OTC Drug Hospital , by Region USD Million (2027-2032)
  • Table 158. OTC Drug Clinic , by Region USD Million (2027-2032)
  • Table 159. OTC Drug Household , by Region USD Million (2027-2032)
  • Table 160. South America OTC Drug, by Country USD Million (2027-2032)
  • Table 161. South America OTC Drug, by Type USD Million (2027-2032)
  • Table 162. South America OTC Drug, by Application USD Million (2027-2032)
  • Table 163. South America OTC Drug, by Form USD Million (2027-2032)
  • Table 164. South America OTC Drug, by End User USD Million (2027-2032)
  • Table 165. Brazil OTC Drug, by Type USD Million (2027-2032)
  • Table 166. Brazil OTC Drug, by Application USD Million (2027-2032)
  • Table 167. Brazil OTC Drug, by Form USD Million (2027-2032)
  • Table 168. Brazil OTC Drug, by End User USD Million (2027-2032)
  • Table 169. Argentina OTC Drug, by Type USD Million (2027-2032)
  • Table 170. Argentina OTC Drug, by Application USD Million (2027-2032)
  • Table 171. Argentina OTC Drug, by Form USD Million (2027-2032)
  • Table 172. Argentina OTC Drug, by End User USD Million (2027-2032)
  • Table 173. Rest of South America OTC Drug, by Type USD Million (2027-2032)
  • Table 174. Rest of South America OTC Drug, by Application USD Million (2027-2032)
  • Table 175. Rest of South America OTC Drug, by Form USD Million (2027-2032)
  • Table 176. Rest of South America OTC Drug, by End User USD Million (2027-2032)
  • Table 177. Asia Pacific OTC Drug, by Country USD Million (2027-2032)
  • Table 178. Asia Pacific OTC Drug, by Type USD Million (2027-2032)
  • Table 179. Asia Pacific OTC Drug, by Application USD Million (2027-2032)
  • Table 180. Asia Pacific OTC Drug, by Form USD Million (2027-2032)
  • Table 181. Asia Pacific OTC Drug, by End User USD Million (2027-2032)
  • Table 182. China OTC Drug, by Type USD Million (2027-2032)
  • Table 183. China OTC Drug, by Application USD Million (2027-2032)
  • Table 184. China OTC Drug, by Form USD Million (2027-2032)
  • Table 185. China OTC Drug, by End User USD Million (2027-2032)
  • Table 186. Japan OTC Drug, by Type USD Million (2027-2032)
  • Table 187. Japan OTC Drug, by Application USD Million (2027-2032)
  • Table 188. Japan OTC Drug, by Form USD Million (2027-2032)
  • Table 189. Japan OTC Drug, by End User USD Million (2027-2032)
  • Table 190. India OTC Drug, by Type USD Million (2027-2032)
  • Table 191. India OTC Drug, by Application USD Million (2027-2032)
  • Table 192. India OTC Drug, by Form USD Million (2027-2032)
  • Table 193. India OTC Drug, by End User USD Million (2027-2032)
  • Table 194. South Korea OTC Drug, by Type USD Million (2027-2032)
  • Table 195. South Korea OTC Drug, by Application USD Million (2027-2032)
  • Table 196. South Korea OTC Drug, by Form USD Million (2027-2032)
  • Table 197. South Korea OTC Drug, by End User USD Million (2027-2032)
  • Table 198. Taiwan OTC Drug, by Type USD Million (2027-2032)
  • Table 199. Taiwan OTC Drug, by Application USD Million (2027-2032)
  • Table 200. Taiwan OTC Drug, by Form USD Million (2027-2032)
  • Table 201. Taiwan OTC Drug, by End User USD Million (2027-2032)
  • Table 202. Australia OTC Drug, by Type USD Million (2027-2032)
  • Table 203. Australia OTC Drug, by Application USD Million (2027-2032)
  • Table 204. Australia OTC Drug, by Form USD Million (2027-2032)
  • Table 205. Australia OTC Drug, by End User USD Million (2027-2032)
  • Table 206. Rest of Asia-Pacific OTC Drug, by Type USD Million (2027-2032)
  • Table 207. Rest of Asia-Pacific OTC Drug, by Application USD Million (2027-2032)
  • Table 208. Rest of Asia-Pacific OTC Drug, by Form USD Million (2027-2032)
  • Table 209. Rest of Asia-Pacific OTC Drug, by End User USD Million (2027-2032)
  • Table 210. Europe OTC Drug, by Country USD Million (2027-2032)
  • Table 211. Europe OTC Drug, by Type USD Million (2027-2032)
  • Table 212. Europe OTC Drug, by Application USD Million (2027-2032)
  • Table 213. Europe OTC Drug, by Form USD Million (2027-2032)
  • Table 214. Europe OTC Drug, by End User USD Million (2027-2032)
  • Table 215. Germany OTC Drug, by Type USD Million (2027-2032)
  • Table 216. Germany OTC Drug, by Application USD Million (2027-2032)
  • Table 217. Germany OTC Drug, by Form USD Million (2027-2032)
  • Table 218. Germany OTC Drug, by End User USD Million (2027-2032)
  • Table 219. France OTC Drug, by Type USD Million (2027-2032)
  • Table 220. France OTC Drug, by Application USD Million (2027-2032)
  • Table 221. France OTC Drug, by Form USD Million (2027-2032)
  • Table 222. France OTC Drug, by End User USD Million (2027-2032)
  • Table 223. Italy OTC Drug, by Type USD Million (2027-2032)
  • Table 224. Italy OTC Drug, by Application USD Million (2027-2032)
  • Table 225. Italy OTC Drug, by Form USD Million (2027-2032)
  • Table 226. Italy OTC Drug, by End User USD Million (2027-2032)
  • Table 227. United Kingdom OTC Drug, by Type USD Million (2027-2032)
  • Table 228. United Kingdom OTC Drug, by Application USD Million (2027-2032)
  • Table 229. United Kingdom OTC Drug, by Form USD Million (2027-2032)
  • Table 230. United Kingdom OTC Drug, by End User USD Million (2027-2032)
  • Table 231. Netherlands OTC Drug, by Type USD Million (2027-2032)
  • Table 232. Netherlands OTC Drug, by Application USD Million (2027-2032)
  • Table 233. Netherlands OTC Drug, by Form USD Million (2027-2032)
  • Table 234. Netherlands OTC Drug, by End User USD Million (2027-2032)
  • Table 235. Rest of Europe OTC Drug, by Type USD Million (2027-2032)
  • Table 236. Rest of Europe OTC Drug, by Application USD Million (2027-2032)
  • Table 237. Rest of Europe OTC Drug, by Form USD Million (2027-2032)
  • Table 238. Rest of Europe OTC Drug, by End User USD Million (2027-2032)
  • Table 239. MEA OTC Drug, by Country USD Million (2027-2032)
  • Table 240. MEA OTC Drug, by Type USD Million (2027-2032)
  • Table 241. MEA OTC Drug, by Application USD Million (2027-2032)
  • Table 242. MEA OTC Drug, by Form USD Million (2027-2032)
  • Table 243. MEA OTC Drug, by End User USD Million (2027-2032)
  • Table 244. Middle East OTC Drug, by Type USD Million (2027-2032)
  • Table 245. Middle East OTC Drug, by Application USD Million (2027-2032)
  • Table 246. Middle East OTC Drug, by Form USD Million (2027-2032)
  • Table 247. Middle East OTC Drug, by End User USD Million (2027-2032)
  • Table 248. Africa OTC Drug, by Type USD Million (2027-2032)
  • Table 249. Africa OTC Drug, by Application USD Million (2027-2032)
  • Table 250. Africa OTC Drug, by Form USD Million (2027-2032)
  • Table 251. Africa OTC Drug, by End User USD Million (2027-2032)
  • Table 252. North America OTC Drug, by Country USD Million (2027-2032)
  • Table 253. North America OTC Drug, by Type USD Million (2027-2032)
  • Table 254. North America OTC Drug, by Application USD Million (2027-2032)
  • Table 255. North America OTC Drug, by Form USD Million (2027-2032)
  • Table 256. North America OTC Drug, by End User USD Million (2027-2032)
  • Table 257. United States OTC Drug, by Type USD Million (2027-2032)
  • Table 258. United States OTC Drug, by Application USD Million (2027-2032)
  • Table 259. United States OTC Drug, by Form USD Million (2027-2032)
  • Table 260. United States OTC Drug, by End User USD Million (2027-2032)
  • Table 261. Canada OTC Drug, by Type USD Million (2027-2032)
  • Table 262. Canada OTC Drug, by Application USD Million (2027-2032)
  • Table 263. Canada OTC Drug, by Form USD Million (2027-2032)
  • Table 264. Canada OTC Drug, by End User USD Million (2027-2032)
  • Table 265. Mexico OTC Drug, by Type USD Million (2027-2032)
  • Table 266. Mexico OTC Drug, by Application USD Million (2027-2032)
  • Table 267. Mexico OTC Drug, by Form USD Million (2027-2032)
  • Table 268. Mexico OTC Drug, by End User USD Million (2027-2032)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global OTC Drug: by Type USD Million (2019-2024)
  • Figure 5. Global OTC Drug: by Application USD Million (2019-2024)
  • Figure 6. Global OTC Drug: by Form USD Million (2019-2024)
  • Figure 7. Global OTC Drug: by End User USD Million (2019-2024)
  • Figure 8. South America OTC Drug Share (%), by Country
  • Figure 9. Asia Pacific OTC Drug Share (%), by Country
  • Figure 10. Europe OTC Drug Share (%), by Country
  • Figure 11. MEA OTC Drug Share (%), by Country
  • Figure 12. North America OTC Drug Share (%), by Country
  • Figure 13. Global OTC Drug share by Players 2024 (%)
  • Figure 14. Global OTC Drug share by Players (Top 3) 2024(%)
  • Figure 15. Global OTC Drug share by Players (Top 5) 2024(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Eli Lily (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lily (United States) Revenue: by Geography 2024
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2024
  • Figure 21. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi (France) Revenue: by Geography 2024
  • Figure 23. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Abbott Laboratories (United States) Revenue: by Geography 2024
  • Figure 25. Amgen(United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen(United States) Revenue: by Geography 2024
  • Figure 27. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca (United Kingdom) Revenue: by Geography 2024
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2024
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2024
  • Figure 33. Roche Holdings (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche Holdings (Switzerland) Revenue: by Geography 2024
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2024
  • Figure 37. Global OTC Drug: by Type USD Million (2027-2032)
  • Figure 38. Global OTC Drug: by Application USD Million (2027-2032)
  • Figure 39. Global OTC Drug: by Form USD Million (2027-2032)
  • Figure 40. Global OTC Drug: by End User USD Million (2027-2032)
  • Figure 41. South America OTC Drug Share (%), by Country
  • Figure 42. Asia Pacific OTC Drug Share (%), by Country
  • Figure 43. Europe OTC Drug Share (%), by Country
  • Figure 44. MEA OTC Drug Share (%), by Country
  • Figure 45. North America OTC Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lily (United States)
  • Pfizer (United States)
  • Sanofi (France)
  • Abbott Laboratories (United States)
  • Amgen(United States)
  • AstraZeneca (United Kingdom)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
  • Roche Holdings (Switzerland)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Lifecare Innovations (India) , GlaxoSmithKline (United Kingdom)
Select User Access Type

Key Highlights of Report


Jun 2023 215 Pages 56 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global OTC Drug Quantitative research analysis
Global OTC Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Eli Lily (United States), Pfizer (United States), Sanofi (France), Abbott Laboratories (United States), Amgen(United States), AstraZeneca (United Kingdom), Merck & Co. (United States), Novartis (Switzerland), Roche Holdings (Switzerland) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The ongoing industry reorganization involving acquisitions in recent years has led to a tendency among pharmaceutical companies. " is seen as one of major influencing trends for OTC Drug Market during projected period 2024-2032.
The OTC Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global OTC Drug Report?

Have a Query? Click Here

Other Related Reports

Biopharmaceutical Logistics Comprehensive Study by Type (Cold Chain Logistics, Non-Cold Chain Logistics), End Users (Clinics, Pharmacies, Hospitals, Pharmaceuticals, Biopharmaceuticals, Supermarkets,...
$ 3450
Amoxicillin Comprehensive Study by Application (Skin Infections, ENT (Ear, Nose & Throat) Infections, Stomach Infections, Lungs Infections, Urinary tract infections (UTI), Pneumonia, Bronchitis, Gono...
$ 3650
Lutein Supplements Comprehensive Study by Nature (Organic, Synthetic), Form (Powder, Tablets, Oil Suspension, Emulsion, Others), Distribution Channel (Online Stores, Medical Stores, Nutraceutical Sto...
$ 3650
Multiple Sclerosis Drugs Comprehensive Study by Type (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary-Progressive MS (PPMS), Secondary-Progressive MS (SPMS)), Route of Admi...
$ 3450
Dog Care Comprehensive Study by Type (Dog Food, Treats & Chews, Toys & Training, Apparel & Accessories, Grooming & Healthcare, Shelter & Accessories, Other), Application (Young Dogs, Old Dogs), Distr...
$ 3450
Human DNA Vaccines Comprehensive Study by Type (Human DNA vaccines, Animal DNA vaccines), Application (Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung canc...
$ 3750